Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy

Heart

Volumn 92, Issue 5, 2006, Pages 615-618

  Komamura, K ^a   Sasaki, T ^b   Hanatani, A ^a   Kim, J ^a   Hashimura, K ^a   Ishida, Y ^a   Ohkaru, Y ^c   Asayama, K ^c   Tanaka, T ^d   Ogai, A ^a   Nakatani, T ^a   Kitamura, S ^a   Kangawa, K ^a   Miyatake, K ^a   Kitakaze, M ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FATTY ACID BINDING PROTEIN; MARKER; TROPONIN T;

ADULT; AGED; ARTICLE; ASSISTED CIRCULATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HEART ASSIST DEVICE; HEART DEATH; HEART EJECTION FRACTION; HEART RATE; HEART TRANSPLANTATION; HOSPITAL DISCHARGE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; UNIVARIATE ANALYSIS;

BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; DEATH, SUDDEN, CARDIAC; FATTY ACID-BINDING PROTEINS; FEMALE; HEART RATE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; STROKE VOLUME; SURVIVAL RATE; TROPONIN T;

EID: 33646244983     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.043067     Document Type: Article

References (21)

1. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994;331:1564-75.
2. Remme WJ, Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
3. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
4. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7.
5. Schirmer H, Omland T. Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromso study. Eur Heart J 1999;20:755-63.
6. Buckley MG, Sethi D, Markandu ND, et al. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci (Lond) 1992;83:437-44.
7. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-3.
8. Ohta Y, Watanabe K, Nakazawa M, et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol 2000;36:S19-23.
9. Schaap FG, van der Vusse GJ, Glatz JF. Fatty acid-binding proteins in the heart. Mol Cell Biochem 1998;180:43-51.
10. Okamoto F, Sohmiya K, Ohkaru Y, et al. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction: clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med 2000;38:231-8.
11. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996;93:841-2.
12. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1:3-14.
13. Edwards WD, Holmes DR Jr, Reeder GS. Diagnosis of active lymphocytic myocarditis by endomyocardial biopsy: quantitative criteria for light microscopy. Mayo Clin Proc 1982;57:419-25.
14. Katsuragi M, Yutani C, Imakita M, et al. Cell infiltration caused deterioration in the prognosis of patients with clinical diagnosis of dilated cardiomyopathy (DCM): application of biopsy criteria of myocarditis to 42 autopsy cases. Heart Vessels 1993;8:42-7.
15. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001;103:369-74.
16. Giannitsis E, Muller-Bardorff M, Lehrke S, et al. Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 2001;104:630-5.
17. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333-41.
18. Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002;89:691-5.
19. Goto T, Takase H, Toriyama T, et al. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 2003;89:1303-7.
20. Maisch B, Ristic AD, Hufnagel G, et al. Dilated cardiomyopathies as a cause of congestive heart failure. Herz 2002;27:113-34.
21. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003;107:857-63.